Results 51 to 60 of about 8,611 (185)

Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells.

open access: yesPLoS ONE, 2013
Normal cellular phenotypes that serve an oncogenic function during tumorigenesis are potential candidates for cancer targeting drugs. Within a subset of invasive primary breast carcinoma, we observed relatively abundant expression of Tetherin, a cell ...
Aejaz Sayeed   +5 more
doaj   +1 more source

Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis

open access: yesBMC Cancer, 2009
Background Bone metastases are frequent complications of breast cancer. Recent literature implicates multiple chemokines in the formation of bone metastases in breast cancer.
Zheng Xin   +6 more
doaj   +1 more source

Exchangeability type properties of asset prices

open access: yes, 2011
In this paper we analyse financial implications of exchangeability and similar properties of finite dimensional random vectors. We show how these properties are reflected in prices of some basket options in view of the well-known put-call symmetry ...
Molchanov, Ilya, Schmutz, Michael
core   +1 more source

Mutations accumulated in the Spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin.

open access: yesPLoS Pathogens
BST2/Tetherin is a restriction factor with broad antiviral activity against enveloped viruses, including coronaviruses. Specifically, BST2 traps nascent particles to membrane compartments, preventing their release and spread.
Yuhang Shi   +5 more
doaj   +1 more source

BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma. [PDF]

open access: yesInt J Mol Sci
High-grade gliomas (HGGs, WHO grades 3–4) are highly aggressive, with a poor prognosis and treatment resistance. Immune evasion may contribute to their progression, but the role of cytotoxic T-lymphocyte immune evasion (CTLE) is not well-validated. This study analyzed the transcriptomic data of 525 patients from TCGA-GBM-HG_U133A.
Liao Z   +5 more
europepmc   +2 more sources

TNFRSF11B computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients [PDF]

open access: yes, 2010
Background TNFRSF11B computational development network construction and analysis of frontal cortex of HIV encephalitis (HIVE) is very useful to identify novel markers and potential targets for prognosis and therapy.
Ju X Huang, L Wang, Ming H Jiang
core   +1 more source

CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription

open access: yesCancer Gene Therapy, 2022
AbstractEpigenetic alterations have been functionally linked to ovarian cancer development and occurrence. The CXXC zinc finger protein 1 (CFP1) is an epigenetic regulator involved in DNA methylation and histone modification in mammalian cells. However, its role in ovarian cancer cells is unknown.
Liu-Qing Yang   +19 more
openaire   +2 more sources

Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins. [PDF]

open access: yes, 2019
The plasma membrane is a site of conflict between host defenses and many viruses. One aspect of this conflict is the host's attempt to eliminate infected cells using innate and adaptive cell-mediated immune mechanisms that recognize features of the ...
Guatelli, John   +5 more
core   +1 more source

Functional microarray analysis suggests repressed cell-cell signaling and cell survival-related modules inhibit progression of head and neck squamous cell carcinoma [PDF]

open access: yes, 2011
Background: Cancer shows a great diversity in its clinical behavior which cannot be easily predicted using the currently available clinical or pathological markers.
Anna EL Coló   +9 more
core   +2 more sources

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

open access: yesAdvanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy